PRESS RELEASE published on 06/30/2025 at 19:37, 7 months ago Inside Information / Other news releases GeNeuro announces approval of all resolutions proposed at Extraordinary General Meeting with 69.1% share capital representation. Jesús Martin-Garcia named Executive Chairman Shareholders EGM Resolutions GeNeuro Jesús Martin-Garcia
BRIEF published on 06/12/2025 at 22:47, 7 months 18 days ago GeNeuro SA: Judicial recovery for its French subsidiary Restructuring GeNeuro SA Judicial Recovery French Subsidiary Judicial Administrator
PRESS RELEASE published on 06/12/2025 at 22:42, 7 months 18 days ago Inside Information / Other news releases GeNeuro SA's French subsidiary GeNeuro Innovation SAS enters receivership proceedings amidst parent company's debt-restructuring efforts Autoimmune Diseases GeNeuro SA Neurodegenerative Diseases Debt-restructuring Receivership Proceedings
BRIEF published on 12/13/2024 at 12:02, 1 year 1 month ago Citigroup reduces its stake in GENEURO SA Euronext Paris Sale Of Shares Threshold Crossing GeNeuro SA Citigroup
BRIEF published on 12/06/2024 at 18:35, 1 year 1 month ago GeNeuro's New Precision Medicine for ALS Unveiled Precision Medicine GeNeuro ALS Treatment GNK-301 HERV-K ENV
PRESS RELEASE published on 12/06/2024 at 18:30, 1 year 1 month ago Inside Information / Other news releases GeNeuro presents groundbreaking findings on precision medicine for ALS patients with GNK-301 at the 35th International Symposium on ALS/MND. Research highlights potential of targeting HERV-K ENV to transform ALS treatment Precision Medicine ALS GeNeuro GNK-301 HERV-K ENV
BRIEF published on 11/06/2024 at 09:48, 1 year 2 months ago Crossing of thresholds by Invus Public Equities in GENEURO SA Euronext Paris Capital Increase Crossing Thresholds GeNeuro SA Invus Public Equities
BRIEF published on 06/28/2024 at 07:05, 1 year 7 months ago GeNeuro announces the results of the GNC-501 trial in post-Covid-19 syndrome Business Strategy Clinical Test GeNeuro Temelimab Post-Covid-19 Syndrome
PRESS RELEASE published on 06/28/2024 at 07:00, 1 year 7 months ago Inside Information / Other news releases GeNeuro announces results of the GNC-501 study addressing post-COVID-19 neuropsychiatric syndromes. Initial findings show no significant improvement with temelimab treatment compared to placebo GeNeuro Temelimab Neuropsychiatric Post-Covid-19 Syndrome GNC-501 Study
BRIEF published on 06/14/2024 at 18:35, 1 year 7 months ago GeNeuro Announces Unanimous Approval of Resolutions at AGM Shareholders Biopharmaceutical AGM Resolutions GeNeuro
Published on 01/31/2026 at 03:15, 9 hours 47 minutes ago Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 10 hours 42 minutes ago Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 11 hours 22 minutes ago Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/30/2026 at 23:00, 14 hours 2 minutes ago Avidian Gold Corp. Announces Director Resignation
Published on 01/31/2026 at 12:25, 37 minutes ago JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 10 hours 17 minutes ago CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 15 hours 2 minutes ago Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 16 hours 52 minutes ago Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 20:09, 16 hours 53 minutes ago Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 17:45, 19 hours 17 minutes ago Schneider Electric launches a capital increase reserved for employees
Published on 01/29/2026 at 18:00, 1 day 19 hours ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 19 hours ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 19 hours ago Cegedim generated LFL revenue growth of 1.1% in 2025
